Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Expert Rev Respir Med. 2021 Oct;15(10):1303-1316. doi: 10.1080/17476348.2021.1937132. Epub 2021 Jun 9.
: Severe asthma and chronic rhinosinusitis (CRS), with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP), are heterogeneous diseases characterized by different mechanistic pathways (endotypes) and variable clinical presentations (phenotypes).: This review provides the clinician with an overview of the prevalence and clinical impact of severe chronic upper and lower airways disease and suggests a novel therapeutic approach with biological agents with possible biomarkers. To select relevant literature for inclusion in this review, we conducted a literature search using the PubMed database, using terms 'severe airways disease' AND 'endotype' AND 'treatment.' The literature review was performed for publication years 2010-2020, restricting the articles to humans and English language publications.: The coronavirus disease (COVID-19) pandemic has brought forth many challenges for patients with severe airway disease and healthcare practitioners involved in care. These patients could have an increased risk of developing severe SARS-CoV-2 disease, although treatment with biologics is not associated with a worse prognosis. Eosinopenia on hospital admission plays a key role as a diagnostic and prognostic biomarker.
严重哮喘和慢性鼻-鼻窦炎（CRS），伴鼻息肉（CRSwNP）和不伴鼻息肉（CRSsNP），是具有不同发病机制（表型）和不同临床表现（表型）的异质性疾病。本综述为临床医生提供了关于严重慢性上、下呼吸道疾病的患病率和临床影响的概述，并提出了一种新的治疗方法，即使用生物制剂治疗可能有生物标志物。为了选择本综述中包含的相关文献，我们使用 PubMed 数据库进行了文献检索，使用的术语是“严重气道疾病”和“表型”和“治疗”。文献综述的出版年份为 2010-2020 年，将文章限制在人类和英语出版物范围内。冠状病毒病（COVID-19）大流行给严重气道疾病患者和参与护理的医疗保健从业者带来了许多挑战。这些患者可能有发展严重 SARS-CoV-2 疾病的风险增加，尽管生物制剂治疗与预后恶化无关。入院时的嗜酸性粒细胞减少症是一种关键的诊断和预后生物标志物。
